Zacks2d agoneutral
4 Biotech Stocks Likely to Outpace Q2 Earnings EstimatesMedical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
531last 24h
2512last 7d
483● bullish (7d)
257● bearish (7d)
197publishers
Barrons.com6d agoneutral
Bristol Myers Raises Earnings Guidance as Newer Drugs Drive Big Quarterly BeatBristol Myers Squibb faces declining revenue in its legacy drug portfolio, but new products like Opdivo are offsetting the drop.
Moby6d agoneutral
Anika Therapeutics, Inc. Q2 2026 Earnings Call SummaryMoby summary of Anika Therapeutics, Inc.'s Q2 2026 earnings call
Reuters Videos11d agoneutralVIDEO
Nasdaq lags on angst over AI spending ahead of earnings reports<body><p>STORY: U.S. stocks ended mixed on Friday, with the Dow gaining just under half a percent, the S&P 500 virtually flat and the tech-heavy Nasdaq sliding nearly two-thirds of a percent.</p><p>The S&P 500 technology index underperformed the broader market as chip stocks fell, with Intel dropping nearly 8% despite forecasting quarterly profit and revenue above Wall Street estimates.</p><p>Enthusiasm for the AI trade weakened after Alphabet's announcement earlier this week of a plan to hike capital spending even as it burns cash.</p><p>Richard Reyle, chief investment officer at Questar Capital Partners, said that as a result investors are rotating into what he called "safer parts of the market."</p><p>"Pharmaceuticals have been flying, and that's been, I think, where we see the rotation of the market right now. [FLASH] You look at the iShares, pharmaceutical fund, it's big components that are J&J and Eli Lilly, they're at all-time highs. And they're still relatively not super expensive stocks. So I think that's a place that can be bought and held. And of course, energy. Exxon's going to announce earnings next week. I bet they're going to be a blockbuster and they're going to continue to be because they make money at $60 a barrel. At $100 a barrel, forget about it. They do very well."</p><p>The S&P 500 real estate sector also outperformed during the session. Its leading gainer was Digital Realty Trust, which rallied 11% after it raised its full-year forecast for funds from operations.</p><p>Among other gainers, shares of SLB climbed 11% after the oilfield services firm beat expectations for second-quarter profit.</p><p>Investors now turn their attention to quarterly results next week from Magnificent 7 megacaps Microsoft, Amazon, Meta and Apple.</p></body>
Motley Fool16d agobullish
Is It Too Late to Buy Johnson & Johnson After Its Blowout Earnings Report?J&J has more than 28 sources of blockbuster revenue.
Zacks19d agoneutral
Sector ETFs to Win on Q2 Earnings Growth PotentialQ2 earnings are off to a strong start. Tech, Energy, Materials, Finance and Aerospace ETFs could shine as profit growth broadens across sectors.
Motley Fool20d agobullish
Is Johnson & Johnson a Buy After Its Latest Earnings Report?Investors didn't seem to think so after the company published it.
GuruFocus.com20d agoneutral
Johnson & Johnson (JNJ) Q2 2026 Earnings Call Highlights: Strong Sales Growth and Raised ...Johnson & Johnson (JNJ) reports robust sales growth and raises full-year guidance, despite facing headwinds from STELARA and challenges in the MedTech segment.
Proactive21d agobullish
Johnson & Johnson beats Q2 estimates, raises full-year 2026 guidanceJohnson & Johnson (NYSE:JNJ) reported better-than-expected second quarter results and raised its full-year 2026 outlook, as strong pharmaceutical sales helped offset headwinds from products facing patent competition. The healthcare company posted adjusted earnings per share of $2.90 for...
MarketBeat21d agoneutral
Johnson & Johnson Q2 Earnings Call HighlightsJohnson & Johnson (NYSE:JNJ) raised its full-year 2026 outlook after reporting second-quarter sales growth that management said was supported by strength in Innovative Medicine, new product launches and a broad portfolio that helped offset continued pressure from STELARA biosimilar competition.
Quartz21d agobullish
Johnson & Johnson Q2 2026 earnings beat on medicines unit strengthThe healthcare company posted $25.31 billion in quarterly sales and raised its annual sales forecast to about $101.1 billion at the midpoint
InvestorsHub21d agobullish
Johnson & Johnson tops second-quarter forecasts and lifts guidance despite premarket decline (JNJ)Johnson & Johnson (NYSE:JNJ) reported stronger-than-expected second-quarter results and raised its full-year earnings outlook, although the healthcare company’s shares slipped around 1 percent in premarket trading on Wednesday. Earnings and revenue beat expectationsThe company posted adjusted earnings per share of 2.
Investing.com21d agobullish
Johnson & Johnson beats estimates but shares dipInvesting.com -- Johnson & Johnson (NYSE:JNJ) reported second-quarter results that exceeded Wall Street expectations, though shares are down around 1% premarket on Wednesday.
Reuters21d agobullish
J&J quarterly earnings beat Wall Street estimates on strength of medicines unitBy Michael Erman July 15 (Reuters) - Johnson & Johnson beat Wall Street estimates for second-quarter sales and profit on Wednesday, as strong growth from immunology drug Tremfya and cancer blockbuster
Proactive29d agobearish
Nasdaq seen down and Dow up as Samsung earnings hit AI stocksUS markets are set for a mixed open on Tuesday, with technology stocks expected to come under pressure after Samsung delivered record quarterly profits that still failed to satisfy investors, raising fresh questions about AI valuations. Nasdaq futures were down 1.1% ahead of the opening bell,...
Investor's Business Daily29d agobullish
Johnson & Johnson, IBD Stock Of The Day, In Buy Zone Heading Into EarningsJohnson & Johnson stock is Monday's IBD Stock Of The Day. The medical bellwether will report its June-quarter earnings next week.
Yahoo Finance Video40d agobearishVIDEO
Big Tech stocks tumble while Micron continues to gain on Q3 earningsUS stocks (^DJI, ^IXIC, ^GSPC) search for direction ahead of Thursday's session close, while Micron Technology (MU) holds onto gains following its massive earnings beat yesterday. Yahoo Finance Markets and Data Editor Jared Blikre takes a closer look at the day's market moves, Big Tech stocks, and how Micron's stock gains may be impacting Apple (AAPL).
Barchart41d agoneutral
Johnson & Johnson Earnings Preview: What to ExpectJohnson & Johnson is scheduled to report its second-quarter results next month, and analysts expect a single-digit earnings rise.
The Wall Street Journal62d agobullish
Medtronic Stock Jumps on Strong EarningsShares of Medtronic jumped 5% Wednesday after the medical-device maker reported better-than-expected quarterly results, helped by strong sales of devices used in heart procedures. The company also said it applied for U.
Barrons.com63d agobearish
Medtronic Stock Is Defying a Market Selloff After Earnings. Here’s Why.The medical device maker posts fiscal fourth-quarter earnings and revenue that narrowly beat analysts’ estimates.
MarketBeat81d agoneutral
Stereotaxis Q1 Earnings Call HighlightsStereotaxis (NYSEAMERICAN:STXS) said its first-quarter results did not yet reflect what management described as a major commercial transition driven by new regulatory approvals, new catheter products and the launch of its GenesisX robotic system. Chairman and CEO David Fischel told investors that t
Zacks84d agobullish
Halozyme's Q1 Earnings & Revenues Beat Estimates, Stock UpHALO beats Q1 earnings estimates as royalty revenues from partner drugs and strong product sales lift revenues by 42% year over year.
MarketBeat90d agoneutral
J & J Snack Foods Q2 Earnings Call HighlightsJ & J Snack Foods (NASDAQ:JJSF) reported fiscal second-quarter 2026 results that showed margin expansion and higher adjusted earnings despite a decline in sales, as management pointed to benefits from its “Project Apollo” transformation and ongoing portfolio reshaping. Chief Executive Officer D